This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA: Watch Out for Fake Adderall
Counterfeit Pills Contain Pain Medication, Not CNS Stimulants
By News Staff
"Adderall contains four active ingredients -- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate," said a May 29 FDA news release. "Instead of these active ingredients, the counterfeit product contained tramadol and acetaminophen, which are ingredients in medicines used to treat acute pain."
Adderall currently is on the FDA drug shortage list because of supply issues involving some of its active ingredients, further fueling concerns that people will buy the drug online. According to FDA officials, "rogue websites and distributors" may target hard-to-get drugs for counterfeiting.
Authentic Adderall tablets are round, orange/peach in color and scored, with "dp" embossed on one side and "30" on the other. The real tablets are packaged only in a 100-count bottle with the National Drug Code (NDC) 0555-0768-02 listed.
The counterfeit Adderall tablets, on the other hand, come in a blister package and are white, round and smooth, with no markings. The counterfeit product also may have misspellings on the package, such as "NDS" instead of "NDC," "Aspartrte" instead of "Aspartate" or "Singel" instead of "Single."
The counterfeit version of Adderall should be considered unsafe, ineffective and potentially harmful.
FDA officials are urging patients who think they have received counterfeit Adderall to stop taking the product and contact their health care professional. In addition, these consumers are asked to contact the FDA's Office of Criminal Investigations by calling (800) 551-3989 or via the FDA website.
Adverse events that may be related to use of these products can be reported to MedWatch, the FDA's Safety Information and Adverse Event Reporting Program.